Depending on how you do the calculation, Alza Corp. just sold itself to Johnson & Johnson [See Deal] for nearly twice what Abbott Laboratories Inc. had been willing to pay almost two years before [See Deal]—about $45 a share in J&J stock vs. a split-adjusted $22 a share in Abbott stock in June 1999. (See"Alza Takes Independence Road to Acquisition," IN VIVO, July 1999 [A#1999800166 and "The FTC Takes a Closer Look at Consolidation," IN VIVO, December 1999 [A#1999800249.) That works out to about $13 billion—or somewhere in the neighborhood of 45 times projected 2001 earnings.
Not that investors were particularly delighted at this extraordinary price. In the first place, analysts weren't overwhelmed by the doubling...